ÂÜÀòÂÒÂ×

Yang Lou has a diverse work experience in the biotech and biopharmaceutical industry. They are currently serving as the Senior Vice President at ABclonal Technology since March 2021. Previously, they worked as a Director at the same company from January 2021 to February 2022.

Prior to ABclonal Technology, Yang Lou was the CEO of Yurogen Biosystems LLC starting from April 2015. Yurogen Biosystems is a biotech company focused on producing high-quality antibodies and antibody-based products.

Before entering the industry, Yang Lou worked at UMass Medical School for a long period, starting as a Post-doctoral researcher in March 2005 and then becoming an Instructor from January 2010 to March 2015. At UMass Medical School, they conducted research on rabbit monoclonal antibodies, evaluating their function and immunogenicity.

Yang Lou's career started at the University of Science and Technology of China, where they obtained their Ph.D. degree. During their time there from September 1999 to March 2005, they conducted studies on key protein interaction networks, toxicological research, and biological characterization.

Overall, Yang Lou has gained extensive experience in various roles and responsibilities, showcasing their expertise in the biotech industry.

Yang Lou received a Ph.D. in Cell Biology from the University of Science and Technology of China in the years 1999-2005. Prior to that, from 1995-1999, Yang Lou attended Nanjing University, although the degree attained and field of study during that time are unknown.